- Home
- SANG vs CRBU Comparison
SANG vs CRBU Comparison
Compare SANG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- CRBU
- Stock Information
- Founded
- SANG 1984
- CRBU 2011
- Country
- SANG Canada
- CRBU United States
- Employees
- SANG N/A
- CRBU N/A
- Industry
- SANG Computer Software: Programming Data Processing
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- SANG Technology
- CRBU Health Care
- Exchange
- SANG Nasdaq
- CRBU Nasdaq
- Market Cap
- SANG 194.3M
- CRBU 165.8M
- IPO Year
- SANG 2021
- CRBU 2021
- Fundamental
- Price
- SANG $5.92
- CRBU $1.83
- Analyst Decision
- SANG
- CRBU Strong Buy
- Analyst Count
- SANG 0
- CRBU 3
- Target Price
- SANG N/A
- CRBU $6.67
- AVG Volume (30 Days)
- SANG 2.2K
- CRBU 718.1K
- Earning Date
- SANG 11-05-2025
- CRBU 11-05-2025
- Dividend Yield
- SANG N/A
- CRBU N/A
- EPS Growth
- SANG N/A
- CRBU N/A
- EPS
- SANG N/A
- CRBU N/A
- Revenue
- SANG $238,264,000.00
- CRBU $9,121,000.00
- Revenue This Year
- SANG N/A
- CRBU $9.23
- Revenue Next Year
- SANG $2.38
- CRBU N/A
- P/E Ratio
- SANG N/A
- CRBU N/A
- Revenue Growth
- SANG N/A
- CRBU N/A
- 52 Week Low
- SANG $4.08
- CRBU $0.66
- 52 Week High
- SANG $7.99
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- SANG 55.67
- CRBU 48.14
- Support Level
- SANG $5.42
- CRBU $1.77
- Resistance Level
- SANG $5.74
- CRBU $1.92
- Average True Range (ATR)
- SANG 0.16
- CRBU 0.12
- MACD
- SANG -0.00
- CRBU -0.01
- Stochastic Oscillator
- SANG 59.52
- CRBU 15.42
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.